Document:

Letter Agreement (Warrant), dated October 3, 2001

 Exhibit 10.20 
 Eyeblaster Ltd. 
 7 Zarchin Street 
 Ra’anana
Israel 43100 
  

	Re:	Grant of Options/Waiver of Claims 

 Gentlemen: 
 I, Gal Trifon, hereby acknowledge and confirm as follows: 
  

	 	1.	In my capacity as an employee of Eyeblaster Ltd. (the “Company”), the Company has paid to me (or, with respect to managerial insurance and continuing education payments,
to a fund established in my benefit) the amounts set forth in Exhibit A (the “Consideration”) as payment of my salary, social and other benefits in consideration of the performance of my duties for the company during the period,
since I start working for the Company, commencing 15 August, 1999 and ending 31 July, 2001 (the “Relevant Period”). 

  

	 	2.	I agree that, notwithstanding anything to the contrary contained in the Employment Agreement between the Company and the undersigned, dated 15 August, 1999 (the
“Employment Agreement”), the payment of the Consideration represents payment in full of the salary and social benefits for the Relevant Period. 

  

	 	3.	In consideration of my agreement to waive any demands or claims of additional compensation to which I was entitled under the Employment Agreement, eyeblaster, Inc. shall grant to
me, or to any person or entity designated by me, options to purchase 41,389 shares of Common Stock of the eyeblaster, Inc., par value $0.001 (the “Options”). The Options shall be exercisable at any time following 10 years from the grant
thereof, at an exercise price equal to the par value of the shares underlying the Options ($0.001). 

	 	4.	In light of Eyeblaster, Inc.’s undertaking to grant the Options herein, I hereby irrevocably waive any and all present and future claims and demands with respect to the level
of my compensation from the Company, including claims of withheld wages, for the Relevant Period, and release the Company, its directors, officers and employees from any claims or demands in connection therewith. 

  

							
	Signed:	  		  	
			
	 /s/ Gal Trifon
	  		  	
	Name:	 	Gal Trifon	  		  	
	Date:	 	Oct. 3, 2001	  		  	

 Accepted and agreed: 
  

							
	Eyeblaster, Ltd.	  		  	
				
	By:	 	 /s/ Gal Trifon
	  		  	
	Title:	 	CEO	  		  	
	Date:	 	Oct. 3, 2001	  		  	

 In light of the waiver of claims contained herein, Eyeblaster, Inc, hereby undertakes to issue to
Gal Trifon, or to any person or entity designated by him, options to purchase 41,389 shares of Common Stock of the Company, par value $0.001, exercisable on the terms described in Section 3 above, in accordance with the terms and conditions of
a Stock Option Plan to be approved by the Board of Directors of the Company. 
  

							
	Eyeblaster, Ltd.	  		  	
				
	By:	 	 /s/ Gal Trifon
	  		  	
	Title:	 	CEO	  		  	
	Date:	 	Oct. 3, 2001	  		  	

  

 2Letter Agreement (Warrant), dated October 4, 2001

 Exhibit 10.21 
 Eyeblaster Ltd. 
 7 Zarchin Street 
 Ra’anana
Israel 43100 
  

	Re:	Grant of Options/Waiver of Claims 

 Gentlemen: 
 I, Ofer Zadikario, hereby acknowledge and confirm as follows: 
  

	 	1.	In my capacity as an employee of Eyeblaster Ltd. (the “Company”), the Company has paid to me (or, with respect to managerial insurance and continuing education payments,
to a fund established in my benefit) the amounts set forth in Exhibit A (the “Consideration”) as payment of my salary, social and other benefits in consideration of the performance of my duties for the company during the period,
since I start working for the Company, commencing 1 September, 1999 and ending 31 July, 2001 (the “Relevant Period”). 

  

	 	2.	I agree that, notwithstanding anything to the contrary contained in the Employment Agreement between the Company and the undersigned, dated 1 September, 1999 (the
“Employment Agreement”), the payment of the Consideration represents payment in full of the salary and social benefits for the Relevant Period. 

  

	 	3.	In consideration of my agreement to waive any demands or claims of additional compensation to which I was entitled under the Employment Agreement, eyeblaster, Inc. shall grant to
me, or to any person or entity designated by me, options to purchase 38,414 shares of Common Stock of the eyeblaster, Inc., par value $0.001 (the “Options”). The Options shall be exercisable at any time following 10 years from the grant
thereof, at an exercise price equal to the par value of the shares underlying the Options ($0.001). 

	 	4.	In light of Eyeblaster, Inc.’s undertaking to grant the Options herein, I hereby irrevocably waive any and all present and future claims and demands with respect to
the level of my compensation from the Company, including claims of withheld wages, for the Relevant Period, and release the Company, its directors, officers and employees from any claims or demands in connection therewith.

  

							
	Signed:	  		  	
			
	 /s/ Ofer Zadikario
	  		  	
	Name:	 	Ofer Zadikario	  		  	
	Date:	 	23/9/2001	  		  	

 Accepted and agreed, 
 Eyeblaster, Ltd. 
  

							
	By:	 	 /s/ Gal Trifon
	  		  	
	Title:	 	CEO	  		  	
	Date:	 	Oct. 4, 2001	  		  	

 In light of the waiver of claims contained herein, Eyeblaster, Inc, hereby undertakes to issue to
Ofer Zadikario, or to any person or entity designated by him, options to purchase 38,414 shares of Common Stock of the Company, par value $0.001, exercisable on the terms described in Section 3 above, in accordance with the terms and conditions
of a Stock Option Plan to be approved by the Board of Directors of the Company. 
 Eyeblaster, Inc. 
  

							
	By:	 	 /s/ Gal Trifon
	  		  	
	Title:	 	CEO	  		  	
	Date:	 	Oct. 4, 2001	  		  	

  

 2Transcript of March 7, 2008 Senetek Shareholder Conference Call

 Exhibit 10.1 
 Senetek PLC 
 Shareholder Conference Call 
 March 7, 2008 
 12:00 pm Eastern Standard Time 
 OPERATOR: 
 “This conference call is being provided for informational and discussion purposes, and is not intended to
provide and should not be relied upon as investment advice or an opinion regarding the appropriateness or suitability of any investment. Nothing herein should be construed to be an offer to sell, or a solicitation of an offer to buy any securities.

 This discussion will contain forward-looking statements regarding future events. These statements are just predictions and are subject to risks and
uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include failure to get regulatory approval for our product candidates, market acceptance for approved products, management of rapid
growth, risks of regulatory review and clinical trials, intellectual property risks, and the need to acquire additional products. We would like to refer our audience to the documents that Senetek’s files from time to time with the
Securities and Exchange Commission.” 
 “I would now like to turn it over to Frank Massino, Chief Executive Officer of Senetek PLC.”

 FRANK: 
 Thank you for joining us, the purpose of today’s
call is to update investors on recent developments – as well as discussion of business strategies and initiatives – and the status of ancillary products. 
  

 -1- 

 On Monday we announced that Senetek has entered into a dispute resolution process with Triax Aesthetics LLC – the
pharmaceutical marketer which Senetek licensed to sell Senetek’s proprietary product, Pyratine 6TM, in the ethical market which includes dermatologists, dispensing and non-dispensing physicians and “behind the counter” sales in
pharmacies. 
 The License and Distribution Agreement we entered into with Triax Aesthetics last August provides that if either party has issues with the
other party’s performance, there is a 3 week informal dispute resolution period followed by binding arbitration. 
 The Agreement requires both sides to
maintain strict confidentiality about any dispute, and therefore we cannot address specific issues raised . . . . .we recognize your frustration as a shareholder from the many calls that we have received and continue to receive questions asking us
how sales of Pyratine-6TM are tracking; but unfortunately, we cannot answer this as we have not received a report on sales other than an informal update in early January. 
  

 -2- 

 However, the Agreement is public information and under this Agreement Senetek’s obligations regard product
development and manufacturing – and Triax’s obligations have to do with: 
  

	 	•	 	 Setting up a Sales Force 

  

	 	•	 	 Organizing and Implementing the Marketing Campaign – and 

  

	 	•	 	 Organizing and Implementing the Sales Program 

 We
will meet with Triax to attempt to resolve our respective issues through the informal dispute resolution process. Under the Agreement if informal efforts do not resolve our dispute by late March, then either side can demand binding arbitration.

 We will press release significant updates when they occur, subject to confidentiality provisions. And although we would like to elaborate further on the
dispute resolution process, we are prohibited from doing so and therefore, in this conference call, we believe that it is in all of our best interest not to take questions today. 
  

 -3- 

 However, I would like to take this opportunity to share with you the events taking place at Senetek which we believe are
collectively most positive: 
 Pyratine-6TM clinical study results were featured in the February issue of the Journal, “Drugs in Dermatology.”
In the article, it was reported that Pyratine-6TM demonstrated efficacy in the reduction of fine lines and wrinkles, skin roughness, mottled hyperpigmentation, and in the improvement of skin moisture content. In addition to the efficacy in the
improvement in photodamaged skin overall, an important finding of this study is the significant reduction in erythema at 2 weeks and the additional reductions at weeks 4, 8, and 12. It has been noted that this is the first report to show reduced
erythema associated with use of a non-prescription topical product. 
 An additional clinical study for the treatment of Acne Rosacea is nearing completion
at the University of California, Irvine and we look forward to updating you on the study results shortly. At the request of the investigators and subjects, we are continuing this study for another nine months due to its early positive results.

  

 -4- 

 As you know two leading physicians have recently presented on Pyratine-6TM at major dermatological conferences,
Dr. Neil Sadick at the American Academy of Dermatology and Dr. Mark Nestor at the South Beach Dermatology Meeting. In addition, Dr. Arisa Ortiz of the Department of Dermatology at the University of California at Irvine is scheduled to
present a clinical update on the treatment of acne rosacea with Pyratine-6TM at the upcoming International Investigative Dermatology Conference in Kyoto, Japan in May of this year. 
 There is great significance in such early endorsements by key physicians of a new product. We are working on additional formulations and combinations of Pyratine-6TM and hope to have additional products available
in the near future products that continue to offer differential advantages over the competition. 
  

 -5- 

 Regarding our Business Strategy and Initiatives . . . . 
 We continue to implement our previously stated strategy to move our dermatology and skin care business from an exclusively royalty based model to a model concentrating on more fully integrated sales and marketing with
the goal of achieving greater revenues in an accelerated timeframe. 
 We have hired and contracted key resources through a previously budgeted program to
facilitate further accelerated commercialization of our products. Marjorie Hays has returned to become the Head of our Communications, having spent the last few months redesigning our new website which has received rave reviews, generating more
inquires on Senetek shares and technology. Marjorie will be working on IR and PR campaigns designed to increase visibility on the company. Mike brings much needed pharmaceutical experience in sales and marketing as well as business development,
having experience with companies such as Pfizer, Glaxo Smith Kline and PARI Pharmaceuticals. In addition, we have signed Phillip Rose to a consultancy arrangement that specifically deals with 

  

 -6- 

 
revenue generation. You may remember Phil as the former Vice President and General Manager of North American Operations for ICN Pharmaceuticals, now Valeant
Pharmaceuticals . . . . . Phil was the internal champion of Kinerase, having branded this product and being responsible for its early success. 
 We are
currently in discussions for several license arrangements for our second generation products in foreign markets to include Asia, Australia and Europe. 
 We
have accelerated development of two additional compounds in our portfolio, PA100 and AK801 and are currently completing safety testing, readying the products for human clinical trials. We have targeted PA100 for the treatment of wound healing and we
are also establishing protocols to test our already clinically proven product, 4HBAP for acne vulgaris, the number one disease state seen by dermatologists, representing an incredibly large market. 
  

 -7- 

 Moving onto Invicorp® and Reliaject®, I would like to report that Invicorp® is currently being marketed in Denmark and
is being rapidly embraced by the physicians. Sales of Invicorp® in Denmark, although relatively small in number, are projected to capture in excess of a 50% market share of the alternative
treatments for erectile dysfunction. This positive feedback is significant and validates the excellent efficacy and safety profile of Invicorp® and will be useful in the successful
marketing of the product in Europe and the United States. 
 Along with the question on how
Pyratine-6TM sales are tracking, the other most frequent inquiry that we get from shareholders is “what is the effect of the recent announcement by Ardana being up for sale will have on Invicorp®?” Ardana has announced that it is looking to be acquired and this may indeed impact the advancement of the Mutual Recognition Process for Invicorp® in
Europe . . . . however, Invicorp® is a valuable asset to Ardana and any prospective owner. 
 Ardana has informed us in writing that all requirements are complete to advance the MRP. We have just recently
negotiated back from Ardana the return of the valuable rights for Invicorp® for BRIC . . . . the territories of Brazil, India, China and Russia and now are in collective negotiations with
Plethora, our partner for Invicorp® in the US market and with Ranbaxy, our partner for the Reliaject® 
  

 -8- 

 We are pleased to report that Plethora continues to operate to its
plan of having Invicorp® in the US market around the fourth quarter of 2009. Just recently Plethora was able to successfully demonstrate the safety of Invicorp® to the FDA, addressing the age old non-issue of the report of brown fatty spots in mice, a major step forward. 
 I would like to remind you that the successful approval of Invicorp® in both European countries and the United States triggers large milestone payments to Senetek by its respective licensees. 
 We are pleased to update you on Reliaject® as Ranbaxy
continues to make great progress in readying it’s facility for the manufacture of this proprietary delivery system and are quite confident that they will have multiple products delivered in the Reliaject® with its first commercialization taking place in 2009. 
  

 -9- 

 Updates from the Polish Academy of Sciences are positive on the treatment of Glio blastoma multiforme, a deadly cancer of
the brain. One of the objectives that we have set for Mike is to begin preparing and positioning this excellent and breakthrough treatment, readying it for outlicensing to major pharma. 
 Turning to financial and administrative matters, we have completed our application for listing on the American Stock Exchange. We have been quite pleased with their reception, however, now that the stock is trading
well below the $3 range, we believe that Senetek’s listing on this exchange is in jeopardy at this time. It is not unlike the difficulty that many companies today are having in executing an IPO. 
 We will keep you updated on this important objective targeted for completion in the year 2008. 
 As many of you know, we are prohibited by UK regulations from buying back our own shares under our current capital structure. We believe strongly in implementing a buy back program and therefore have initiated the
process to petition the UK Courts to restructure our capital in order to allow us the ability to repurchase Senetek shares and pay dividends. We believe that this would be a 

  

 -10- 

 
prudent and wise use of our funds as our stock currently trades significantly below our cash value . . . . an objective under valuation to say the least,
particularly when coupled with the commercial contracts already in place for the Monoclonal Antibodies, Invicorp® and Reliaject®
.. . . not to mention our rich technology portfolio. 
 Finally, we are concluding our year end
financial work for 2007. Fourth quarter results will be ready on March 31st. We are in the best position ever in the long and storied history of Senetek with $18 Million of cash on hand, no debt, two new dermatological products ready for
commercialization (Pyratine-6TM and 4HBAP), significant commercial contracts in place for the Monoclonal Antibodies, Invicorp® and Reliaject® and continuing success with new Intellectual Properties such as the RNA interference treatment sequence for brain tumors as well as new and unique compounds such as PA100 and AK801. 
 This concludes our conference call. . . . . We invite you to contact Senetek through IR@Senetek.net or to call our Head of Communications, Marjorie Hays at
707-226-3900 extension 102. Thank you for your interest, your patience and your support. Have a Great Weekend. 
 Good day. 
  
 OPERATOR: 
 Thank you for your participation in Senetek’s conference call. You may now disconnect. 
 END 
  

 -11-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00138-of-00352.parquet"}]]